Argentex Share Discussion Threads

[ali47fish] 24/5/2024 07:20

never mind beckwith- what does this do for retail investors is it good for us- hvent added so far

[mighunter] 23/5/2024 18:10

Raymondmoz, the thing that wasn't mentioned to you in the replies but is only a few posts before yours is that Argentex require an element of cash collateral to do business, particularly with Forward contracts. If you want another example of this, look at the Cash TCAP hold relative to their market cap. For both AGFX/TCAP you can't just extract it down to Zero. It is important to note that they are not therefore spending all the £18m cash on turning around the business plus the £3.5m from the fundraise, of the £18m cash they will only be spending the surplus element not needed for collateral. Admittedly we are not given that figure.

[raymondmoz] 22/5/2024 12:53

Dr Biotech et al thanks for confirming. I needed a sense check and appreciate your time replying. Never seen a market cap so low with that much cash in bank. Feels to me like the original founders took it as far as they could. Now the new CEO and CFO will take it to the next stage witrh a fresh perspective. I expect there will be some serious cost cutting going on within the business; cutting the fat etc. Excited to see the next set of figures. This looks like pocket change to a bank. Rember what Santander did with Ebury all those years ago. Now they are eyeing an IPO.

[mr roper] 22/5/2024 08:13

Sprung to life

[silverlandfinance] 22/5/2024 08:01

Raymondmoz
I agree with you that the shares are incredibly cheap.
The company is profitable and cash generative having a cash balance at the last count of £18.3million, augmented by the recent fund raise. Yet the market value is languishing. around £40million








































































Raymondmoz
I agree with you that the share price is incredibly cheap. The company is cash generative and debt free. The £18.3m cash balances are augement by the rececent fund raise (appx £3.5m), yet the

[silverlandfinance] 22/5/2024 08:01

Raymondmoz
I agree with you that the shares are incredibly cheap.
The company is profitable and cash generative having a cash balance at the last count of £18.3million, augmented by the recent fund raise. Yet the market value is languishing. around £40million








































































Raymondmoz
I agree with you that the share price is incredibly cheap. The company is cash generative and debt free. The £18.3m cash balances are augement by the rececent fund raise (appx £3.5m), yet the

[dr biotech] 21/5/2024 20:53

Thats correct - but the current management in their wisdom think they may need to sink that into the business. Its a strategy that is somewhat risky imo.

[raymondmoz] 21/5/2024 20:39

Hi, first time posting, I am quite interested in AGFX. It feels incredibly cheap and as its an AIM stock very little coverage and liquidity which presents its own problems. I am trying to work out the investment case right now: Market cap circa: 45M GBP, PE ratio approx 9. The bit I cant understand is the cash. From the full year results "Debt free and cash generative with net cash increasing by £2.1m in FY23 to £18.3m (2)
" and "2 Net cash represents cash and cash equivalents less amounts payable to clients" Am I missing something?? They have 18.3M cash but the but the Market Cap is 45M ?

[silverlandfinance] 20/5/2024 12:22

I just bought 40,000 at 36.23p
There is appx 25% discrepancy between the 45p the institutions have paid(I am assuming that they have more information as to what is happening in the company than the ordinary investor) and what the market is paying.
I hope I am right.

[thaiger] 19/5/2024 22:33

Sir John Beckwith via Pacific Investment, Children Trust, Personal Pension and Charitable Trust; increased holding from 15% to 18.80% on 13/5/24.Very puzzled by share price reactions to fund raised, time will tell, I guess!?!

[thaiger] 14/5/2024 09:02

Five Directors took part in the placing at 45p!Management must have convincing stories to tell Institutions who took part in the placing. We do not know the stories but time will tell.

[dr biotech] 09/5/2024 19:47

Retail offer raised just under £2k. Surprised it raised that much.

[ali47fish] 09/5/2024 18:43

9 May 2024



Argentex Group PLC

(the "Company")

PDMR Dealing



Argentex Group PLC (AIM: AGFX) announces that David Winney, Chief Compliance and Risk Officer, on 7 May 2024 purchased 50,000 ordinary shares of £0.0001 each ("Ordinary Shares") in the Company at a price of 36 pence per Ordinary Share.

Following this transaction, David Winney's total beneficial interest in the Company is 50,000 Ordinary Shares representing approximately 0.04% of the Company's issued share capital.


any significance in this

[toffeeman] 09/5/2024 14:33

Not that bright having bought a lot higher

[phillis] 09/5/2024 13:38

Some bright investors on this bb

[toffeeman] 09/5/2024 12:20

Why on earth would we when we can buy at a 25% discount!

[thaiger] 09/5/2024 10:23

Placing already done at 45p, don't think anybody will take up retail offer!

[adamb1978] 06/5/2024 15:11

Thanks Dorian. I agree with your comments on the forecasts - if you look at CSFS in H2 2023, the forecasts for 2024 are utterly nonsensical, unless after rapid growth the company hit a wall at the end of the year.

I'm surprised that they didnt try to make more of the differentiation which you mention in the prospectus, then again I guess they were so much smaller at the time that just associating themselves with company's several times bigger was viewed enough.

As I said, I only have a small position in CSFS however given the apparent more challenging trading seen by AGFX, I was interested in people's views on the difference given I invest almost solely by numbers.

Looking forward to CSFS' results on Wed, and will leave this board in peace now (though I think discussing peers' performance is relevant to any company...)

[ali47fish] 06/5/2024 13:54

please dont overuse acronyms -what is csfs- and how does this relate to the process for the open offer/ placing etc.....

[dorian12] 06/5/2024 13:32

CSFS have been beating forecasts. 2023 revenue was originally forecast at £5.7m at the start of the year and actually came in at £9.6m. Likewise I expect the 2024 broker forecast of £11.3m to be well beaten.

[dorian12] 06/5/2024 13:24

I think AGFX and CSFS are different businesses. CSFS is doing a great job at being a cross border fx payment provider to HNWI and corporates, almost wholly with spot deals (and therefore no collateral requirements).